See the DrugPatentWatch profile for Agalsidase
What is agalsidase?
Agalsidase is an enzyme-replacement therapy for Fabry disease. It replaces the missing or deficient enzyme alpha-galactosidase A, helping break down a type of fat (globotriaosylceramide, Gb3) that builds up when the enzyme is not working properly [1].
Which agalsidase products are used?
Agalsidase is used as two branded formulations:
- agalsidase alfa (marketed as Replagal)
- agalsidase beta (marketed as Fabrazyme) [1]
How is agalsidase given, and how often?
Both agalsidase alfa and agalsidase beta are given by intravenous infusion (into a vein) in a clinical setting. The typical dosing interval for Fabry disease is every 2 weeks [1].
Who uses agalsidase and what conditions does it treat?
Agalsidase is indicated for Fabry disease. It is used to treat the underlying enzyme deficiency and reduce the harmful buildup of Gb3. It is commonly considered for patients with confirmed Fabry disease who need enzyme replacement therapy [1].
What are the main side effects people ask about?
Infusion-related reactions are the most commonly discussed risks with intravenous enzyme replacement therapies, including symptoms that can occur during or shortly after the infusion. As with other infused biologics, clinicians also monitor patients for hypersensitivity reactions [1].
How does agalsidase compare with newer Fabry treatments?
Agalsidase is an enzyme replacement therapy (delivered intravenously). Newer Fabry treatments may include other approaches to Fabry disease management, but agalsidase specifically works by supplying the missing enzyme [1].
Where does agalsidase fit with lab monitoring?
Patients receiving agalsidase are usually monitored over time to assess disease impact, which can include tracking biomarkers and clinical status. Monitoring plans depend on the patient and the treatment regimen [1].
Sources
[1] https://www.drugs.com/ingredient/agalsidase.html